社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
neolt
IP属地：未知
+关注
帖子 · 22
帖子 · 22
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
neolt
neolt
·
2021-08-27
I like
非常抱歉，此主贴已删除
看
1,010
回复
2
点赞
2
编组 21备份 2
分享
举报
neolt
neolt
·
2021-07-09
I like
Nvidia, Pfizer, Mastercard — Halftime Report traders answer your stock questions during the sell-off
CNBC’s “Halftime Report” traders answered questions from CNBC Pro subscribersamid Thursday’s sell-of
Nvidia, Pfizer, Mastercard — Halftime Report traders answer your stock questions during the sell-off
看
2,041
回复
评论
点赞
2
编组 21备份 2
分享
举报
neolt
neolt
·
2021-06-17
Great
Intel CEO sees ’10 good years’ of chip industry growth
KEY POINTS Intel CEO Pat Gelsinger said that he expects 10 “good years” of growth in the semiconduc
Intel CEO sees ’10 good years’ of chip industry growth
看
1,900
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
neolt
neolt
·
2021-06-17
I like
非常抱歉，此主贴已删除
看
1,598
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
neolt
neolt
·
2021-06-17
I like
Apple Struggles in Push to Make Healthcare Its Greatest Legacy
Tech giant has envisioned hiring doctors to offer primary care, now focused on Watch Under the leade
Apple Struggles in Push to Make Healthcare Its Greatest Legacy
看
1,949
回复
评论
点赞
2
编组 21备份 2
分享
举报
neolt
neolt
·
2021-06-17
I like
Amazon Stock: Is The Rebirth Of FAAMG Imminent?
Amazon shares have been a relative loser this year, but stocks have taken a pause in the past weeks.
Amazon Stock: Is The Rebirth Of FAAMG Imminent?
看
1,070
回复
评论
点赞
1
编组 21备份 2
分享
举报
neolt
neolt
·
2021-06-15
I like
非常抱歉，此主贴已删除
看
1,733
回复
评论
点赞
1
编组 21备份 2
分享
举报
neolt
neolt
·
2021-06-11
I like
Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing
Get-rich-quick strategies rarely work.
Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing
看
832
回复
评论
点赞
6
编组 21备份 2
分享
举报
neolt
neolt
·
2021-06-07
Tlry good good
AMC, BlackBerry, Other Stonks Surge In Monday's Pre-Market Session
WallStreetBets-favorite stocks, the so-called stonks, extended minor gains in Monday's pre-market se
AMC, BlackBerry, Other Stonks Surge In Monday's Pre-Market Session
看
1,145
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
neolt
neolt
·
2021-06-02
I like
Coinbase Pro opens up to dogecoin after cryptocurrency's 6,000% gain this year
KEY POINTS Starting Tuesday, Coinbase Pro will accept inbound transfers of dogecoin. Trading will b
Coinbase Pro opens up to dogecoin after cryptocurrency's 6,000% gain this year
看
931
回复
1
点赞
1
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3577345565957074","uuid":"3577345565957074","gmtCreate":1614251542211,"gmtModify":1619100124215,"name":"neolt","pinyin":"neolt","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/6506ceb9a382e3b286894737df1e5530","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":367,"tweetSize":22,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":819371280,"gmtCreate":1630038981340,"gmtModify":1704955021541,"author":{"id":"3577345565957074","authorId":"3577345565957074","name":"neolt","avatar":"https://static.tigerbbs.com/6506ceb9a382e3b286894737df1e5530","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577345565957074","authorIdStr":"3577345565957074"},"themes":[],"htmlText":"I like ","listText":"I like ","text":"I like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/819371280","repostId":"1196717589","repostType":4,"isVote":1,"tweetType":1,"viewCount":1010,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143211982,"gmtCreate":1625795646246,"gmtModify":1631890715064,"author":{"id":"3577345565957074","authorId":"3577345565957074","name":"neolt","avatar":"https://static.tigerbbs.com/6506ceb9a382e3b286894737df1e5530","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577345565957074","authorIdStr":"3577345565957074"},"themes":[],"htmlText":"I like ","listText":"I like ","text":"I like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143211982","repostId":"1147859669","repostType":4,"repost":{"id":"1147859669","kind":"news","pubTimestamp":1625790658,"share":"https://ttm.financial/m/news/1147859669?lang=&edition=full","pubTime":"2021-07-09 08:30","market":"hk","language":"en","title":"Nvidia, Pfizer, Mastercard — Halftime Report traders answer your stock questions during the sell-off","url":"https://stock-news.laohu8.com/highlight/detail?id=1147859669","media":"CNBC","summary":"CNBC’s “Halftime Report” traders answered questions from CNBC Pro subscribersamid Thursday’s sell-of","content":"<div>\n<p>CNBC’s “Halftime Report” traders answered questions from CNBC Pro subscribersamid Thursday’s sell-off.\nThe traders discussed whether to hold ontoMastercardduring its period of stagnation and ifNvidia’...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/08/nvidia-pfizer-mastercard-halftime-report-traders-answer-your-stock-questions-during-the-sell-off.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nvidia, Pfizer, Mastercard — Halftime Report traders answer your stock questions during the sell-off</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNvidia, Pfizer, Mastercard — Halftime Report traders answer your stock questions during the sell-off\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-09 08:30 GMT+8 <a href=https://www.cnbc.com/2021/07/08/nvidia-pfizer-mastercard-halftime-report-traders-answer-your-stock-questions-during-the-sell-off.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CNBC’s “Halftime Report” traders answered questions from CNBC Pro subscribersamid Thursday’s sell-off.\nThe traders discussed whether to hold ontoMastercardduring its period of stagnation and ifNvidia’...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/08/nvidia-pfizer-mastercard-halftime-report-traders-answer-your-stock-questions-during-the-sell-off.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MA":"万事达"},"source_url":"https://www.cnbc.com/2021/07/08/nvidia-pfizer-mastercard-halftime-report-traders-answer-your-stock-questions-during-the-sell-off.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1147859669","content_text":"CNBC’s “Halftime Report” traders answered questions from CNBC Pro subscribersamid Thursday’s sell-off.\nThe traders discussed whether to hold ontoMastercardduring its period of stagnation and ifNvidia’s stock has topped and whether pharmaceutical plays likePfizerare over.\nJosh Brown, co-founder and CEO of Ritholtz Wealth Management, recommended long-term investors hold onto Mastercard.\n“The stock is up 350% in the last five year,” said Brown. “Yes, its had a couple of months where it hasn’t really gone anywhere, but that’s not at all out of character for any of these large-cap technology slash finance companies. They move in spurts.”","news_type":1,"symbols_score_info":{"MA":0.9}},"isVote":1,"tweetType":1,"viewCount":2041,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161120259,"gmtCreate":1623912070971,"gmtModify":1631890715078,"author":{"id":"3577345565957074","authorId":"3577345565957074","name":"neolt","avatar":"https://static.tigerbbs.com/6506ceb9a382e3b286894737df1e5530","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577345565957074","authorIdStr":"3577345565957074"},"themes":[],"htmlText":"Great ","listText":"Great ","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161120259","repostId":"1185234443","repostType":4,"repost":{"id":"1185234443","kind":"news","pubTimestamp":1623901625,"share":"https://ttm.financial/m/news/1185234443?lang=&edition=full","pubTime":"2021-06-17 11:47","market":"us","language":"en","title":"Intel CEO sees ’10 good years’ of chip industry growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1185234443","media":"CNBC","summary":"KEY POINTS\n\nIntel CEO Pat Gelsinger said that he expects 10 “good years” of growth in the semiconduc","content":"<div>\n<p>KEY POINTS\n\nIntel CEO Pat Gelsinger said that he expects 10 “good years” of growth in the semiconductor industry during a panel at CNBC’s Evolve conference on Wednesday.\nThe remark suggests that Intel...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/16/intel-ceo-sees-10-good-years-of-chip-industry-growth.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel CEO sees ’10 good years’ of chip industry growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel CEO sees ’10 good years’ of chip industry growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 11:47 GMT+8 <a href=https://www.cnbc.com/2021/06/16/intel-ceo-sees-10-good-years-of-chip-industry-growth.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nIntel CEO Pat Gelsinger said that he expects 10 “good years” of growth in the semiconductor industry during a panel at CNBC’s Evolve conference on Wednesday.\nThe remark suggests that Intel...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/16/intel-ceo-sees-10-good-years-of-chip-industry-growth.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QCOM":"高通","INTC":"英特尔","NVDA":"英伟达"},"source_url":"https://www.cnbc.com/2021/06/16/intel-ceo-sees-10-good-years-of-chip-industry-growth.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1185234443","content_text":"KEY POINTS\n\nIntel CEO Pat Gelsinger said that he expects 10 “good years” of growth in the semiconductor industry during a panel at CNBC’s Evolve conference on Wednesday.\nThe remark suggests that Intel’s investments in chip production, such as plans to spend $20 billion to build a chip fabrication plant in Arizona, will create capacity that will be used even after the current global microchip shortage abates.\nQualcomm CEO Cristiano Amon said he sees an opportunity to partner with Intel and its foundry service.\n\nPat Gelsinger, CEO of Intel, speaks in Santa Monica, Calif., on March 9, 2017, in a photo taken when he was CEO of VMware.\nIntel CEO Pat Gelsinger said that he expects 10 “good years” of growth in the semiconductor industry during a panel at CNBC’s Evolve conference on Wednesday.\n“We believe the market, the world, is in a very expansionary period,” Gelsinger told CNBC’s Jon Fortt. “I predict there’s 10 good years in front of us, because the world is becoming more digital, and everything digital needs semiconductors.”\nThe remark suggests that Intel’s investments in chip production, such as plans to spend $20 billion to build a chip fabrication plant in Arizona, will create capacity that will be used even after the current global microchip shortage abates. Intel also recently announced plans to become a “foundry,” or a company that manufactures microchips for other companies.\nGelsinger said Intel planned to announce an additional “mega fab” in the U.S. or Europe before the end of the year.\nGelsinger was appearing at a CNBC panel alongside Qualcomm CEO Cristiano Amon. Both started leading their companies earlier this year.\nWhile the companies are rivals, the CEOs downplayed the competition, and suggested the two chipmakers could end up partnering in areas where they don’t overlap. Qualcomm makes (among other things) chips that connect to 5G networks, while Intel mainly builds central processing units (CPUs) that provide base computing power.\n“You know, we are the unquestioned compute leader, and Qualcomm’s the unquestioned comms leader. Compute meets comms. Right, a lot of new use cases,” Gelsinger said.\nAmon said that he believed that Intel’s foundry plan could be an advantage for Qualcomm, which uses outside foundries to make its chips.\n“There’s a lot of opportunities for the companies to cooperate. Look, we look at Intel and Qualcomm at true technology companies in the United States, we do a lot of advanced and fundamental research to push the industry forward,” Amon said.\nThe two companies do share some strategic concerns. They are both likely to be boosted by a package included in a technology bill currently in the U.S. House of Representatives that would provide $52 billion to fund semiconductor research, design and manufacturing.\n“We’re also very happy about building a much more resilient supply chain, with the on-shoring of semiconductor manufacturing, I think that’s also very important,” Amon said. “You need investment at this order of magnitude for that to happen.”\nBoth companies are also closely watching rival Nvidia’s purchase of Arm from SoftBank for $40 billion. Arm technology is especially important for Qualcomm, because it is essential for designing the kind of low-power microprocessors smartphones use.\nThe deal is also making chip companies nervous that they would need to license essential intellectual property from a competitor, and is facing regulatory challenges in Europe. Currently, Arm doesn’t make any full chips — it just designs underlying technology. On Monday, an Arm spokesperson told CNBC that the company is “extremely confident” that the deal will be approved.\nOver the weekend,Amon told a U.K. newspaper that if the transaction was blocked or Arm otherwise stayed independent, Qualcomm would be interested in investing in Arm.\nWhen asked about Amon’s comment, Gelsinger said: “We are on record saying we’re concerned about the Nvidia-Arm acquisition. And if there were other approaches possible, we’d definitely be interested in understanding them.”","news_type":1,"symbols_score_info":{"INTC":0.9,"NVDA":0.9,"QCOM":0.9}},"isVote":1,"tweetType":1,"viewCount":1900,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161167805,"gmtCreate":1623911960707,"gmtModify":1631890715094,"author":{"id":"3577345565957074","authorId":"3577345565957074","name":"neolt","avatar":"https://static.tigerbbs.com/6506ceb9a382e3b286894737df1e5530","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577345565957074","authorIdStr":"3577345565957074"},"themes":[],"htmlText":"I like","listText":"I like","text":"I like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161167805","repostId":"1104789612","repostType":4,"isVote":1,"tweetType":1,"viewCount":1598,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161164466,"gmtCreate":1623911914255,"gmtModify":1631890715103,"author":{"id":"3577345565957074","authorId":"3577345565957074","name":"neolt","avatar":"https://static.tigerbbs.com/6506ceb9a382e3b286894737df1e5530","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577345565957074","authorIdStr":"3577345565957074"},"themes":[],"htmlText":"I like ","listText":"I like ","text":"I like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161164466","repostId":"1139981231","repostType":4,"repost":{"id":"1139981231","kind":"news","pubTimestamp":1623910261,"share":"https://ttm.financial/m/news/1139981231?lang=&edition=full","pubTime":"2021-06-17 14:11","market":"us","language":"en","title":"Apple Struggles in Push to Make Healthcare Its Greatest Legacy","url":"https://stock-news.laohu8.com/highlight/detail?id=1139981231","media":"The Wall Street Journal","summary":"Tech giant has envisioned hiring doctors to offer primary care, now focused on Watch\nUnder the leade","content":"<p>Tech giant has envisioned hiring doctors to offer primary care, now focused on Watch</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cdcc89ff3fd1e1d8ec3f02f3aaf52457\" tg-width=\"1260\" tg-height=\"840\" referrerpolicy=\"no-referrer\"><span>Under the leadership of CEO Tim Cook, Apple has increased its research-and-development budget eightfold to $20 billion annually.</span></p>\n<p>Apple Inc. Chief Executive Tim Cook has said the company’s greatest contribution to mankind will be in health. So far, some Apple initiatives aimed at broadly disrupting the healthcare sector have struggled to gain traction, according to people familiar with them and documents reviewed by The Wall Street Journal.</p>\n<p>Apple has envisioned an audacious plan for healthcare, offering its own primary-care medical service with Apple-employed doctors at its own clinics, according to people familiar with the plan and documents. To test that and other bold healthcare ideas, it took over clinics that catered to its employees and built a team with scores of clinicians, engineers, product designers and others.</p>\n<p>Today those ambitions, which aren’t widely known, have largely stalled as Apple has shifted the focus of its health unit to something it knows well: Selling devices, specifically the Apple Watch, according to people familiar with its strategy.</p>\n<p>The new primary-care service hasn’t gotten off the ground, people familiar with it say. A digital health app launched quietly this year has struggled to keep users engaged, say people familiar with the app and the documents seen by the Journal. Some employees have raised questions internally about the integrity of health data coming from the company’s clinics that has been used to support product development, according to people familiar with their concerns and the documents.</p>\n<p>An Apple spokesman said data integrity is the foundation for all of the company’s innovations. He pointed to the accomplishments of its health team and said the company is still in the early innings of its work in healthcare, adding that new technology such as heart-rate notifications in products like the Apple Watch have improved users’ health. He said data gathered by Apple’s devices is enabling new research that has the potential to improve care.</p>\n<p>“Many of the assertions in this report are based on incomplete, outdated and inaccurate information,” the spokesman said.</p>\n<p>Looking for new markets where technology can improve efficiency and outcomes—and power sales growth—the tech sector has eyed healthcare as an untapped opportunity. Some of tech’s biggest efforts have failed, includingHaven,Amazon.com Inc.’s high-profile partnership with other companies that aimed to reduce healthcare costs. Today, Amazon has a new effort to sell prescriptions and a plan to launch virtual care across 50 states.</p>\n<p>Under Mr. Cook’s leadership, Apple has increased its research-and-development budget eightfold to $20 billion annually, according to its public filings. And besides a smartwatch, the company has released wireless headphones as well as new services. It has also invested heavily in health, autonomous driving and augmented reality, all technically complex, high-stakes areas, meaning that game-changing offerings could be years away or never come.</p>\n<p>Apple can study markets for years before coming up with its own offering, and it sometimes works extensively on new projects or technologies that it ultimately doesn’t bring to market.</p>\n<p>One of its most ambitious healthcare ideas was a plan to offer primary-care medicine, conceived in 2016, according to documents and the people familiar with the plan. An Apple team spent months trying to figure out how the flood of health and wellness data collected from users of its smartwatch, first released in 2015, might be used to improve healthcare, the people said.</p>\n<p>Apple Chief Operating Officer Jeff Williams, who oversees the health team, urged employees to think big. He said Apple should disrupt what he called the “363” and “break fix” model of care in the U.S., where patients may not see their doctors 363 days a year and only visit when something goes wrong, according to people familiar with his ideas.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/837161c8fc0a7b93c5c67936fe293453\" tg-width=\"1260\" tg-height=\"840\"><span>Apple Chief Operating Officer Jeff Williams oversees its health unit.</span></p>\n<p>The team decided one of the best ways to realize that vision was to provide a medical service of its own, said people familiar with the plan, linking data generated by Apple devices with virtual and in-person care provided by Apple doctors. Apple would offer primary care, but also continuous health monitoring as part of a subscription-based personalized health program, according to these people and the documents.</p>\n<p>If Apple could prove that its combination of device sensors, software and services could improve people’s health and lower costs, the company could franchise the model to health systems and even other countries, according to the documents.</p>\n<p>To start, Apple chose to test the service out on its own employees. Apple took over employee health clinics near its headquarters that were being run by a startup and turned them into test beds for new health services, say people familiar with the changes. In 2017 it hired Dr. Sumbul Desai from Stanford University to run the effort, which was given the code name Casper, said the people familiar with the plan.</p>\n<p>The effort continues today, but Apple has struggled to move Casper past a preliminary stage, say people familiar with its operations.</p>\n<p>Dr. Desai’s unit in particular has seen multiple departures by employees who say its culture discourages critical feedback, which is potentially problematic for a unit focused on products and services related to personal health, according to people familiar with its culture and the documents. Some employees expressed concerns that internal data about the clinics’ performance, data that was recently used to support the rollout of a new digital health app, has been inaccurate or compiled haphazardly, according to the documents and people familiar with the data.</p>\n<p>Those issues have been repeatedly voiced to Messrs. Cook and Williams, according to the documents and people familiar with the issues.</p>\n<p>Apple’s spokesman said such criticisms are inaccurate.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/01a35a283d15f6de16455cae846a617b\" tg-width=\"1260\" tg-height=\"840\"><span>Dr. Sumbul Desai runs a team that oversees clinics, handles relations with regulators and spearheads research collaborations.</span></p>\n<p>Employees concerned about the culture pointed to a 2019 meeting during which a midlevel manager raised questions about data, according to people familiar with the meeting and the documents. Dr. Desai responded angrily, leading some present to conclude that critical questions were unwelcome, according to the people and the documents. The manager left Apple weeks later and the episode contributed to her departure, documents show.</p>\n<p>Apple’s spokesman said Dr. Desai spoke to the importance of data integrity in the meeting. “This matter was investigated thoroughly and the allegations could not be substantiated,” the spokesman said. Apple declined to comment on the circumstances of the employee’s departure.</p>\n<p>The spokesman said the company is proud of Dr. Desai’s work and that she has been instrumental in much of its healthcare work.</p>\n<p>Mr. Williams and Dr. Desai didn’t respond to a request for comment and Apple declined to make them available.</p>\n<p>In addition to overseeing the clinics, known as AC Wellness, Dr. Desai’s team handles relations with regulators, spearheads research collaborations and provides clinical expertise on other health products at Apple.</p>\n<p>A recent initiative for Dr. Desai’s team, a digital health app called HealthHabit that is being tested on California-based Apple employees, has struggled with low engagement since the app’s launch roughly six months ago, according to documents and people familiar with the app.</p>\n<p>HealthHabit offers to connect people with clinicians via chat and encourages them to set health challenges such as “I will exercise more this week.” Those with a history of hypertension can be connected to health coaches who can send them a blood-pressure monitor and scale and advise them on healthier habits.</p>\n<p>Half the people who had downloaded it as of May hadn’t enrolled and engagement among many who have enrolled has been low, according to the documents and people familiar with the app.</p>\n<p>Data supporting the app’s hypertension program has caused new concerns among employees about the integrity of internal data and analysis, some of the people said.</p>\n<p>During a presentation for all Apple health employees in March, Mr. Williams praised the clinics’ results in treating hypertension and pointed to them as evidence supporting the HealthHabit app’s potential, according to people who saw the presentation. He suggested that the company may have wider ambitions for the app if it is successful, they said.</p>\n<p>In the meeting, Mr. Williams showed data indicating that 91% of patients in Apple’s clinics with more severe stage-two hypertension improved to healthier stages or normal, according to documents reviewed by the Journal, a figure that some employees feared could overstate the clinics’ success, according to people who attended the meeting and documents.</p>\n<p>Rival companies offering hypertension apps have disclosed lower rates of success. Hello Heart Inc. reported 23% of stage 2 patients saw a significant improvement in blood pressure at 6 weeks. Livongo claimed one-third of patients with stage one hypertension or worse improved to an elevated or normal range in 6 weeks. Mr. Williams’s data didn’t include a time frame, according to the documents.</p>\n<p>The Apple spokesman said that other companies analyze their hypertension data differently and that the data cited by Mr. Williams in the meeting was for an internal pilot, not a product.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Struggles in Push to Make Healthcare Its Greatest Legacy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Struggles in Push to Make Healthcare Its Greatest Legacy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 14:11 GMT+8 <a href=https://www.wsj.com/articles/apple-struggles-in-push-to-make-healthcare-greatest-legacy-11623832200?mod=hp_lead_pos3><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tech giant has envisioned hiring doctors to offer primary care, now focused on Watch\nUnder the leadership of CEO Tim Cook, Apple has increased its research-and-development budget eightfold to $20 ...</p>\n\n<a href=\"https://www.wsj.com/articles/apple-struggles-in-push-to-make-healthcare-greatest-legacy-11623832200?mod=hp_lead_pos3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.wsj.com/articles/apple-struggles-in-push-to-make-healthcare-greatest-legacy-11623832200?mod=hp_lead_pos3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139981231","content_text":"Tech giant has envisioned hiring doctors to offer primary care, now focused on Watch\nUnder the leadership of CEO Tim Cook, Apple has increased its research-and-development budget eightfold to $20 billion annually.\nApple Inc. Chief Executive Tim Cook has said the company’s greatest contribution to mankind will be in health. So far, some Apple initiatives aimed at broadly disrupting the healthcare sector have struggled to gain traction, according to people familiar with them and documents reviewed by The Wall Street Journal.\nApple has envisioned an audacious plan for healthcare, offering its own primary-care medical service with Apple-employed doctors at its own clinics, according to people familiar with the plan and documents. To test that and other bold healthcare ideas, it took over clinics that catered to its employees and built a team with scores of clinicians, engineers, product designers and others.\nToday those ambitions, which aren’t widely known, have largely stalled as Apple has shifted the focus of its health unit to something it knows well: Selling devices, specifically the Apple Watch, according to people familiar with its strategy.\nThe new primary-care service hasn’t gotten off the ground, people familiar with it say. A digital health app launched quietly this year has struggled to keep users engaged, say people familiar with the app and the documents seen by the Journal. Some employees have raised questions internally about the integrity of health data coming from the company’s clinics that has been used to support product development, according to people familiar with their concerns and the documents.\nAn Apple spokesman said data integrity is the foundation for all of the company’s innovations. He pointed to the accomplishments of its health team and said the company is still in the early innings of its work in healthcare, adding that new technology such as heart-rate notifications in products like the Apple Watch have improved users’ health. He said data gathered by Apple’s devices is enabling new research that has the potential to improve care.\n“Many of the assertions in this report are based on incomplete, outdated and inaccurate information,” the spokesman said.\nLooking for new markets where technology can improve efficiency and outcomes—and power sales growth—the tech sector has eyed healthcare as an untapped opportunity. Some of tech’s biggest efforts have failed, includingHaven,Amazon.com Inc.’s high-profile partnership with other companies that aimed to reduce healthcare costs. Today, Amazon has a new effort to sell prescriptions and a plan to launch virtual care across 50 states.\nUnder Mr. Cook’s leadership, Apple has increased its research-and-development budget eightfold to $20 billion annually, according to its public filings. And besides a smartwatch, the company has released wireless headphones as well as new services. It has also invested heavily in health, autonomous driving and augmented reality, all technically complex, high-stakes areas, meaning that game-changing offerings could be years away or never come.\nApple can study markets for years before coming up with its own offering, and it sometimes works extensively on new projects or technologies that it ultimately doesn’t bring to market.\nOne of its most ambitious healthcare ideas was a plan to offer primary-care medicine, conceived in 2016, according to documents and the people familiar with the plan. An Apple team spent months trying to figure out how the flood of health and wellness data collected from users of its smartwatch, first released in 2015, might be used to improve healthcare, the people said.\nApple Chief Operating Officer Jeff Williams, who oversees the health team, urged employees to think big. He said Apple should disrupt what he called the “363” and “break fix” model of care in the U.S., where patients may not see their doctors 363 days a year and only visit when something goes wrong, according to people familiar with his ideas.\nApple Chief Operating Officer Jeff Williams oversees its health unit.\nThe team decided one of the best ways to realize that vision was to provide a medical service of its own, said people familiar with the plan, linking data generated by Apple devices with virtual and in-person care provided by Apple doctors. Apple would offer primary care, but also continuous health monitoring as part of a subscription-based personalized health program, according to these people and the documents.\nIf Apple could prove that its combination of device sensors, software and services could improve people’s health and lower costs, the company could franchise the model to health systems and even other countries, according to the documents.\nTo start, Apple chose to test the service out on its own employees. Apple took over employee health clinics near its headquarters that were being run by a startup and turned them into test beds for new health services, say people familiar with the changes. In 2017 it hired Dr. Sumbul Desai from Stanford University to run the effort, which was given the code name Casper, said the people familiar with the plan.\nThe effort continues today, but Apple has struggled to move Casper past a preliminary stage, say people familiar with its operations.\nDr. Desai’s unit in particular has seen multiple departures by employees who say its culture discourages critical feedback, which is potentially problematic for a unit focused on products and services related to personal health, according to people familiar with its culture and the documents. Some employees expressed concerns that internal data about the clinics’ performance, data that was recently used to support the rollout of a new digital health app, has been inaccurate or compiled haphazardly, according to the documents and people familiar with the data.\nThose issues have been repeatedly voiced to Messrs. Cook and Williams, according to the documents and people familiar with the issues.\nApple’s spokesman said such criticisms are inaccurate.\nDr. Sumbul Desai runs a team that oversees clinics, handles relations with regulators and spearheads research collaborations.\nEmployees concerned about the culture pointed to a 2019 meeting during which a midlevel manager raised questions about data, according to people familiar with the meeting and the documents. Dr. Desai responded angrily, leading some present to conclude that critical questions were unwelcome, according to the people and the documents. The manager left Apple weeks later and the episode contributed to her departure, documents show.\nApple’s spokesman said Dr. Desai spoke to the importance of data integrity in the meeting. “This matter was investigated thoroughly and the allegations could not be substantiated,” the spokesman said. Apple declined to comment on the circumstances of the employee’s departure.\nThe spokesman said the company is proud of Dr. Desai’s work and that she has been instrumental in much of its healthcare work.\nMr. Williams and Dr. Desai didn’t respond to a request for comment and Apple declined to make them available.\nIn addition to overseeing the clinics, known as AC Wellness, Dr. Desai’s team handles relations with regulators, spearheads research collaborations and provides clinical expertise on other health products at Apple.\nA recent initiative for Dr. Desai’s team, a digital health app called HealthHabit that is being tested on California-based Apple employees, has struggled with low engagement since the app’s launch roughly six months ago, according to documents and people familiar with the app.\nHealthHabit offers to connect people with clinicians via chat and encourages them to set health challenges such as “I will exercise more this week.” Those with a history of hypertension can be connected to health coaches who can send them a blood-pressure monitor and scale and advise them on healthier habits.\nHalf the people who had downloaded it as of May hadn’t enrolled and engagement among many who have enrolled has been low, according to the documents and people familiar with the app.\nData supporting the app’s hypertension program has caused new concerns among employees about the integrity of internal data and analysis, some of the people said.\nDuring a presentation for all Apple health employees in March, Mr. Williams praised the clinics’ results in treating hypertension and pointed to them as evidence supporting the HealthHabit app’s potential, according to people who saw the presentation. He suggested that the company may have wider ambitions for the app if it is successful, they said.\nIn the meeting, Mr. Williams showed data indicating that 91% of patients in Apple’s clinics with more severe stage-two hypertension improved to healthier stages or normal, according to documents reviewed by the Journal, a figure that some employees feared could overstate the clinics’ success, according to people who attended the meeting and documents.\nRival companies offering hypertension apps have disclosed lower rates of success. Hello Heart Inc. reported 23% of stage 2 patients saw a significant improvement in blood pressure at 6 weeks. Livongo claimed one-third of patients with stage one hypertension or worse improved to an elevated or normal range in 6 weeks. Mr. Williams’s data didn’t include a time frame, according to the documents.\nThe Apple spokesman said that other companies analyze their hypertension data differently and that the data cited by Mr. Williams in the meeting was for an internal pilot, not a product.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":1949,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161164072,"gmtCreate":1623911852396,"gmtModify":1631890715116,"author":{"id":"3577345565957074","authorId":"3577345565957074","name":"neolt","avatar":"https://static.tigerbbs.com/6506ceb9a382e3b286894737df1e5530","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577345565957074","authorIdStr":"3577345565957074"},"themes":[],"htmlText":"I like","listText":"I like","text":"I like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161164072","repostId":"1134323907","repostType":4,"repost":{"id":"1134323907","kind":"news","pubTimestamp":1623908945,"share":"https://ttm.financial/m/news/1134323907?lang=&edition=full","pubTime":"2021-06-17 13:49","market":"us","language":"en","title":"Amazon Stock: Is The Rebirth Of FAAMG Imminent?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134323907","media":"TheStreet","summary":"Amazon shares have been a relative loser this year, but stocks have taken a pause in the past weeks.","content":"<p>Amazon shares have been a relative loser this year, but stocks have taken a pause in the past weeks. Is this the time for FAAMG stocks to reclaim their role as market outperformers?</p>\n<p>Amazon shares have been a relative loser this year, but stocks have taken a pause in the past weeks. Is this the time for FAAMG stocks to reclaim their role as market outperformers?</p>\n<p>Amazon stock remains a loser in the market so far in 2021. This has been the year to bet on the reopening trade, including those stocks that benefit from a rise in consumer firepower, inflation and even interest rates: brick-and-mortar retail, materials and commodities, financial services, etc.</p>\n<p>In the past couple of weeks, however, the stock market seems to have taken a pause, climbing little and not picking sides in the value vs. growth debate. Could this be a pivotal moment for AMZN stock and its peers? Will the FAAMG group finally rebound?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3bce1e839677a495a20253020579c1fc\" tg-width=\"1200\" tg-height=\"675\"><span>Figure 1: The FAAMG group.</span></p>\n<p><b>Performance in 2021: sleepy</b></p>\n<p>The chart below shows how far behind Amazon has fallen compared to the S&P 500, the industrials-rich Dow and, even more so, the small-cap Russell 2000 index. The 4% return in nearly six months is three to four times worse than the stock’s average performance since the 1997 IPO.</p>\n<p>To be fair, the weakness experienced this year needs to be put within the context of the past 18 months. The 2020 pandemic accelerated trends in online shopping and cloud adoption, both of which are highly bullish for Amazon. Last year, AMZN returned nearly 80%, four times as much as the S&P 500. Now, shares seem to be taking a timeout.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c3fca6462af9a8940aae7f7a84a91702\" tg-width=\"994\" tg-height=\"497\"><span>Figure 2: AMZN vs. S&P 500, DJIA and Russell 2000.</span></p>\n<p><b>The key is probably macroeconomics</b></p>\n<p>A CNBC panel has recently had an interesting conversation about Amazon stock. Fair points were made about business fundamentals and valuations:</p>\n<ul>\n <li>Amazon’s share of US e-commerce flirted with 40% in 2020, an impressive number;</li>\n <li>Amazon should surpass Walmart as the largest US retailer next year;</li>\n <li>Only 15% of the workloads are in the cloud – a growth opportunity for Amazon Web Services;</li>\n <li>The MGM deal should attract attention, traffic and purchases to the Amazon ecosystem;</li>\n <li>On the bearish side, P/E is still high, maybe even relative to earnings growth potential.</li>\n</ul>\n<p>But in the end, probably none of the above will mater to Amazon stock and the FAAMG group in the foreseeable future. The single most important variable that will likely determine what happens to tech growth for the rest of the year, in my view, is the macroeconomic landscape.</p>\n<p>There is little doubt that the global (and the US, even more so) economies are on a path to recovery. This should be good news for companies and stocks across the board. The question is whether post-pandemic growth will push inflation and interest rates much higher than where they currently are.</p>\n<p>If so, AMZN and FAAMG in general are likely to continue underperforming. This is the case because faster-growing companies rely on long-term earnings and cash flow to support their stock prices. When inflation and yields are high, financial results that are expected to be delivered far out in the future are discounted more heavily to present value.</p>\n<p>For these reasons, pay attention to inflation data and the Federal Reserve’s decisions around monetary policy – the next chapter will play out on Wednesday, June 16. They may be determinant in the direction of Amazon stock and other FAAMG names over the next few months.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon Stock: Is The Rebirth Of FAAMG Imminent?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon Stock: Is The Rebirth Of FAAMG Imminent?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 13:49 GMT+8 <a href=https://www.thestreet.com/amazon/news/amazon-stock-is-the-rebirth-faamg-imminent><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon shares have been a relative loser this year, but stocks have taken a pause in the past weeks. Is this the time for FAAMG stocks to reclaim their role as market outperformers?\nAmazon shares have...</p>\n\n<a href=\"https://www.thestreet.com/amazon/news/amazon-stock-is-the-rebirth-faamg-imminent\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://www.thestreet.com/amazon/news/amazon-stock-is-the-rebirth-faamg-imminent","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134323907","content_text":"Amazon shares have been a relative loser this year, but stocks have taken a pause in the past weeks. Is this the time for FAAMG stocks to reclaim their role as market outperformers?\nAmazon shares have been a relative loser this year, but stocks have taken a pause in the past weeks. Is this the time for FAAMG stocks to reclaim their role as market outperformers?\nAmazon stock remains a loser in the market so far in 2021. This has been the year to bet on the reopening trade, including those stocks that benefit from a rise in consumer firepower, inflation and even interest rates: brick-and-mortar retail, materials and commodities, financial services, etc.\nIn the past couple of weeks, however, the stock market seems to have taken a pause, climbing little and not picking sides in the value vs. growth debate. Could this be a pivotal moment for AMZN stock and its peers? Will the FAAMG group finally rebound?\nFigure 1: The FAAMG group.\nPerformance in 2021: sleepy\nThe chart below shows how far behind Amazon has fallen compared to the S&P 500, the industrials-rich Dow and, even more so, the small-cap Russell 2000 index. The 4% return in nearly six months is three to four times worse than the stock’s average performance since the 1997 IPO.\nTo be fair, the weakness experienced this year needs to be put within the context of the past 18 months. The 2020 pandemic accelerated trends in online shopping and cloud adoption, both of which are highly bullish for Amazon. Last year, AMZN returned nearly 80%, four times as much as the S&P 500. Now, shares seem to be taking a timeout.\nFigure 2: AMZN vs. S&P 500, DJIA and Russell 2000.\nThe key is probably macroeconomics\nA CNBC panel has recently had an interesting conversation about Amazon stock. Fair points were made about business fundamentals and valuations:\n\nAmazon’s share of US e-commerce flirted with 40% in 2020, an impressive number;\nAmazon should surpass Walmart as the largest US retailer next year;\nOnly 15% of the workloads are in the cloud – a growth opportunity for Amazon Web Services;\nThe MGM deal should attract attention, traffic and purchases to the Amazon ecosystem;\nOn the bearish side, P/E is still high, maybe even relative to earnings growth potential.\n\nBut in the end, probably none of the above will mater to Amazon stock and the FAAMG group in the foreseeable future. The single most important variable that will likely determine what happens to tech growth for the rest of the year, in my view, is the macroeconomic landscape.\nThere is little doubt that the global (and the US, even more so) economies are on a path to recovery. This should be good news for companies and stocks across the board. The question is whether post-pandemic growth will push inflation and interest rates much higher than where they currently are.\nIf so, AMZN and FAAMG in general are likely to continue underperforming. This is the case because faster-growing companies rely on long-term earnings and cash flow to support their stock prices. When inflation and yields are high, financial results that are expected to be delivered far out in the future are discounted more heavily to present value.\nFor these reasons, pay attention to inflation data and the Federal Reserve’s decisions around monetary policy – the next chapter will play out on Wednesday, June 16. They may be determinant in the direction of Amazon stock and other FAAMG names over the next few months.","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":1070,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184724823,"gmtCreate":1623726367962,"gmtModify":1631890715125,"author":{"id":"3577345565957074","authorId":"3577345565957074","name":"neolt","avatar":"https://static.tigerbbs.com/6506ceb9a382e3b286894737df1e5530","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577345565957074","authorIdStr":"3577345565957074"},"themes":[],"htmlText":"I like ","listText":"I like ","text":"I like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/184724823","repostId":"1147086744","repostType":4,"isVote":1,"tweetType":1,"viewCount":1733,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":181172377,"gmtCreate":1623381611299,"gmtModify":1631890715136,"author":{"id":"3577345565957074","authorId":"3577345565957074","name":"neolt","avatar":"https://static.tigerbbs.com/6506ceb9a382e3b286894737df1e5530","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577345565957074","authorIdStr":"3577345565957074"},"themes":[],"htmlText":"I like","listText":"I like","text":"I like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/181172377","repostId":"2142221222","repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=full","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8 <a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1,"symbols_score_info":{"DXCM":0.9,"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":832,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114803313,"gmtCreate":1623062170532,"gmtModify":1631890715144,"author":{"id":"3577345565957074","authorId":"3577345565957074","name":"neolt","avatar":"https://static.tigerbbs.com/6506ceb9a382e3b286894737df1e5530","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577345565957074","authorIdStr":"3577345565957074"},"themes":[],"htmlText":"Tlry good good","listText":"Tlry good good","text":"Tlry good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114803313","repostId":"1100811212","repostType":4,"repost":{"id":"1100811212","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623058327,"share":"https://ttm.financial/m/news/1100811212?lang=&edition=full","pubTime":"2021-06-07 17:32","market":"us","language":"en","title":"AMC, BlackBerry, Other Stonks Surge In Monday's Pre-Market Session","url":"https://stock-news.laohu8.com/highlight/detail?id=1100811212","media":"Benzinga","summary":"WallStreetBets-favorite stocks, the so-called stonks, extended minor gains in Monday's pre-market se","content":"<p>WallStreetBets-favorite stocks, the so-called stonks, extended minor gains in Monday's pre-market session after a blistering rally observed in a majority of these stocks last week.</p><p>Here's how the top 10 stocks, in terms of mentions on WallStreetBets subreddit as compiled by Quiver Quantitative, traded in the pre-market session:</p><p><b>BlackBerry Ltd</b> BB shares are up 1.44% in early pre-market hours on Monday. Shares of the Canadian enterprise software closed 12.7% lower at $13.86 on Friday. The company's stock has emerged as top WallStreetBets-interest over the past week.</p><p><b>AMC Entertainment Holdings Inc</b> AMC 0.19%shares are up 1.61% in pre-market hours after closing 6.68% lower at $47.91 on Friday. As per a Reuters report, Wall Street traders arecontinuing to bet against the stock,although have reduced their reliance on short selling.</p><p><b>Clean Energy Fuels Corp</b> CLNE shares are up 5.26% pre-market hours on Monday. Shares of the company closed 2.08% higher at $9.31 on Friday.</p><p><b>GameStop Corp</b> GME 0.09% shares are trading 1.47% higher in pre-market hours on Monday. Shares of the video game and consumer electronics retailer closed 3.80% lower at 248.36 on Monday.</p><p><b>Clover Health Investments Corp</b> CLOV shares are up 3.89% in pre-market hours on Monday. The stock closed 3.89% lower at $9 on Friday.</p><p><b>Tilray Inc</b> TLRY shares traded 2.13% higher in pre-market hours on Monday. Shares of the Canadian pharma and cannabis company closed 4.67% lower at $18.80 on Friday.</p><p><b>SPDR S&P 500 ETF Trust</b> SPY 0.04% was marginally up 0.19% in early pre-market hours on Monday. The ETF closed 0.91% higher at $422.60 per share on Friday.</p><p><b>Workhorse Group Inc</b> WKHS shares are up 3.37% in early pre-market hours on Monday after closing 11.65% lower at $13.05 on Friday.</p><p><b>Sundial Growers Inc</b> SNDL shares are up 6.4% in premarket hours on Monday after closing 15.5% lower at $1.09 on Friday.</p><p><b>Palantir Technologies Inc</b> PLTR 0.04% shares fell 0.25% in premarket hours on Monday. Shares of the company had closed 1.69% higher at $24.03 on Friday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC, BlackBerry, Other Stonks Surge In Monday's Pre-Market Session</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC, BlackBerry, Other Stonks Surge In Monday's Pre-Market Session\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-07 17:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>WallStreetBets-favorite stocks, the so-called stonks, extended minor gains in Monday's pre-market session after a blistering rally observed in a majority of these stocks last week.</p><p>Here's how the top 10 stocks, in terms of mentions on WallStreetBets subreddit as compiled by Quiver Quantitative, traded in the pre-market session:</p><p><b>BlackBerry Ltd</b> BB shares are up 1.44% in early pre-market hours on Monday. Shares of the Canadian enterprise software closed 12.7% lower at $13.86 on Friday. The company's stock has emerged as top WallStreetBets-interest over the past week.</p><p><b>AMC Entertainment Holdings Inc</b> AMC 0.19%shares are up 1.61% in pre-market hours after closing 6.68% lower at $47.91 on Friday. As per a Reuters report, Wall Street traders arecontinuing to bet against the stock,although have reduced their reliance on short selling.</p><p><b>Clean Energy Fuels Corp</b> CLNE shares are up 5.26% pre-market hours on Monday. Shares of the company closed 2.08% higher at $9.31 on Friday.</p><p><b>GameStop Corp</b> GME 0.09% shares are trading 1.47% higher in pre-market hours on Monday. Shares of the video game and consumer electronics retailer closed 3.80% lower at 248.36 on Monday.</p><p><b>Clover Health Investments Corp</b> CLOV shares are up 3.89% in pre-market hours on Monday. The stock closed 3.89% lower at $9 on Friday.</p><p><b>Tilray Inc</b> TLRY shares traded 2.13% higher in pre-market hours on Monday. Shares of the Canadian pharma and cannabis company closed 4.67% lower at $18.80 on Friday.</p><p><b>SPDR S&P 500 ETF Trust</b> SPY 0.04% was marginally up 0.19% in early pre-market hours on Monday. The ETF closed 0.91% higher at $422.60 per share on Friday.</p><p><b>Workhorse Group Inc</b> WKHS shares are up 3.37% in early pre-market hours on Monday after closing 11.65% lower at $13.05 on Friday.</p><p><b>Sundial Growers Inc</b> SNDL shares are up 6.4% in premarket hours on Monday after closing 15.5% lower at $1.09 on Friday.</p><p><b>Palantir Technologies Inc</b> PLTR 0.04% shares fell 0.25% in premarket hours on Monday. Shares of the company had closed 1.69% higher at $24.03 on Friday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BB":"黑莓","PLTR":"Palantir Technologies Inc.","CLOV":"Clover Health Corp","SPY":"标普500ETF","WKHS":"Workhorse Group, Inc.","CLNE":"Clean Energy Fuels Corp","TLRY":"Tilray Inc.","SNDL":"SNDL Inc.","AMC":"AMC院线","GME":"游戏驿站"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100811212","content_text":"WallStreetBets-favorite stocks, the so-called stonks, extended minor gains in Monday's pre-market session after a blistering rally observed in a majority of these stocks last week.Here's how the top 10 stocks, in terms of mentions on WallStreetBets subreddit as compiled by Quiver Quantitative, traded in the pre-market session:BlackBerry Ltd BB shares are up 1.44% in early pre-market hours on Monday. Shares of the Canadian enterprise software closed 12.7% lower at $13.86 on Friday. The company's stock has emerged as top WallStreetBets-interest over the past week.AMC Entertainment Holdings Inc AMC 0.19%shares are up 1.61% in pre-market hours after closing 6.68% lower at $47.91 on Friday. As per a Reuters report, Wall Street traders arecontinuing to bet against the stock,although have reduced their reliance on short selling.Clean Energy Fuels Corp CLNE shares are up 5.26% pre-market hours on Monday. Shares of the company closed 2.08% higher at $9.31 on Friday.GameStop Corp GME 0.09% shares are trading 1.47% higher in pre-market hours on Monday. Shares of the video game and consumer electronics retailer closed 3.80% lower at 248.36 on Monday.Clover Health Investments Corp CLOV shares are up 3.89% in pre-market hours on Monday. The stock closed 3.89% lower at $9 on Friday.Tilray Inc TLRY shares traded 2.13% higher in pre-market hours on Monday. Shares of the Canadian pharma and cannabis company closed 4.67% lower at $18.80 on Friday.SPDR S&P 500 ETF Trust SPY 0.04% was marginally up 0.19% in early pre-market hours on Monday. The ETF closed 0.91% higher at $422.60 per share on Friday.Workhorse Group Inc WKHS shares are up 3.37% in early pre-market hours on Monday after closing 11.65% lower at $13.05 on Friday.Sundial Growers Inc SNDL shares are up 6.4% in premarket hours on Monday after closing 15.5% lower at $1.09 on Friday.Palantir Technologies Inc PLTR 0.04% shares fell 0.25% in premarket hours on Monday. Shares of the company had closed 1.69% higher at $24.03 on Friday.","news_type":1,"symbols_score_info":{"AMC":0.9,"BB":0.9,"CLNE":0.9,"CLOV":0.9,"GME":0.9,"PLTR":0.9,"SNDL":0.9,"SPY":0.9,"TLRY":0.9,"WKHS":0.9}},"isVote":1,"tweetType":1,"viewCount":1145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":113894662,"gmtCreate":1622601662556,"gmtModify":1631890715155,"author":{"id":"3577345565957074","authorId":"3577345565957074","name":"neolt","avatar":"https://static.tigerbbs.com/6506ceb9a382e3b286894737df1e5530","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577345565957074","authorIdStr":"3577345565957074"},"themes":[],"htmlText":"I like","listText":"I like","text":"I like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/113894662","repostId":"1100370600","repostType":4,"repost":{"id":"1100370600","kind":"news","pubTimestamp":1622594387,"share":"https://ttm.financial/m/news/1100370600?lang=&edition=full","pubTime":"2021-06-02 08:39","market":"us","language":"en","title":"Coinbase Pro opens up to dogecoin after cryptocurrency's 6,000% gain this year","url":"https://stock-news.laohu8.com/highlight/detail?id=1100370600","media":"CNBC","summary":"KEY POINTS\n\nStarting Tuesday, Coinbase Pro will accept inbound transfers of dogecoin.\nTrading will b","content":"<div>\n<p>KEY POINTS\n\nStarting Tuesday, Coinbase Pro will accept inbound transfers of dogecoin.\nTrading will begin on or after 9 a.m. PT Thursday June 3, if liquidity conditions are met.\n\nCoinbaseis finally ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/coinbase-pro-opens-to-dogecoin-after-currencys-6000percent-gain-this-year.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coinbase Pro opens up to dogecoin after cryptocurrency's 6,000% gain this year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoinbase Pro opens up to dogecoin after cryptocurrency's 6,000% gain this year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-02 08:39 GMT+8 <a href=https://www.cnbc.com/2021/06/01/coinbase-pro-opens-to-dogecoin-after-currencys-6000percent-gain-this-year.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nStarting Tuesday, Coinbase Pro will accept inbound transfers of dogecoin.\nTrading will begin on or after 9 a.m. PT Thursday June 3, if liquidity conditions are met.\n\nCoinbaseis finally ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/coinbase-pro-opens-to-dogecoin-after-currencys-6000percent-gain-this-year.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COIN":"Coinbase Global, Inc."},"source_url":"https://www.cnbc.com/2021/06/01/coinbase-pro-opens-to-dogecoin-after-currencys-6000percent-gain-this-year.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1100370600","content_text":"KEY POINTS\n\nStarting Tuesday, Coinbase Pro will accept inbound transfers of dogecoin.\nTrading will begin on or after 9 a.m. PT Thursday June 3, if liquidity conditions are met.\n\nCoinbaseis finally getting into dogecoin.\nStarting Tuesday, the crypto exchange is offering its Pro users the option to tradedogecoin, a cryptocurrency that was started as a joke and has taken off this year, helped by the frequent tweeting ofTeslaCEOElon Musk.\nDogecoin is currently trading at 32 cents, up almost 6,000% for the year. However, it’s dropped by more than 50% since reaching ahigh in May.\nCoinbase is one of the largest crypto exchanges on the planet, and its Pro service, as the name suggests, is designed for professional traders. Dogecoin is also available for purchase on Robinhood’s app and through Gemini.\nCoinbase said in ablog postthat it will “immediately” begin accepting inbound transfers to Coinbase Pro. If there is enough liquidity, trading of dogecoin will begin on or after 9 a.m. Pacific Time on Thursday, in supported locations. However, trading will be staggered.\nThe company says it plans to launch in three phases: post-only, limit-only and full trading.\n“If at any point one of the new order books does not meet our assessment for a healthy and orderly market, we may keep the book in one state for a longer period of time or suspend trading,” the company wrote, citing itstrading rules.\nDogecoin is not yet available on Coinbase’s primary website or its consumer mobile apps. The company said there will be a “separate announcement if and when this support is added.” For now, that means that retail investors will have to look elsewhere.\nCoinbase, whichwent public in April, makes most of its money from the trading and storage ofbitcoinand ethereum, the largest cryptocurrencies.\nCEO Brian Armstrong has been a public advocate of the meme-inspired dogecoin.On the company’s May 13 earnings call, Armstrong said that “asset addition is something near and dear” to his heart.\nHe referenced dogecoin as one of the cryptocurrencies that’s getting a lot of attention and shared the company’s plan to list the token in six to eight weeks.","news_type":1,"symbols_score_info":{"COIN":0.9}},"isVote":1,"tweetType":1,"viewCount":931,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}